Therna Biosciences
Therna Biosciences is pioneering programmable RNA medicines with RNA-Logix™, an AI platform that unites biology-guided design with lab-in-the-loop validation. The platform leverages proprietary RNA language models trained on high-throughput experimental data to design, test, and optimize mRNA, ASO, and siRNA therapeutics, delivering lab-validated candidates in about a year. Therna is advancing programs across cardiovascular, metabolic, and immunological diseases, including single-patient programs for ultra-rare conditions.
- Drug Discovery & Therapeutics
- Biotechnology
- Artificial Intelligence
- Healthcare Technology
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Traditional drug development relies on trial-and-error approaches that often fail to precisely control RNA therapeutics, leading to suboptimal efficacy, off-target effects, and lengthy development timelines. The complexity of RNA biology and the vast sequence design space make it difficult to predict how sequence changes affect translation, stability, immune response, and tissue specificity using conventional methods.
Solution
Therna Biosciences provides an integrated RNA intelligence platform, RNA-Logix™, that unites biology-guided AI design with lab-in-the-loop experimental validation to rapidly design, test, and optimize programmable RNA medicines. The platform uses RNA language models trained on large-scale proprietary experimental datasets to understand how sequence design influences therapeutic performance, enabling precise control over mRNA coding sequences and rational design of ASOs and siRNAs. AI-generated designs are continuously evaluated using proprietary experimental datasets from in-house testing in primary cells and in vivo preclinical models, with results fed back to strengthen predictive accuracy with each iteration. This iterative system reduces uncertainty and enables a faster, more reliable path from sequence design to validated therapeutic candidates across multiple RNA modalities.
Target Audience
Therna serves biopharmaceutical companies and clinical researchers developing RNA-based therapies, as well as patients with cardiovascular, metabolic, and immunological diseases and ultra-rare conditions who lack conventional treatment options.
Features
- RNA language models (T-Series) trained on proprietary data generated by Chronos to predict translation, stability, immune response, and tissue/cell specificity
- Chronos high-throughput assay measures thousands of synthetic modified mRNAs across roughly 50 cell contexts over multi-day windows in a single experiment
- Proto design language solves for multiple RNA attributes simultaneously, drawing on orthogonal T-Series models
- BioReason-RNA reasoning model that generates visible chains of biological reasoning for proposed mechanisms
- Clotho automation engine runs the recursive loop, testing hypotheses against proprietary data without requiring a new experiment each cycle
- Platform supports design across three modalities: mRNA, antisense oligonucleotides (ASOs), and small interfering RNAs (siRNAs), with differentiated ASO capability that can both silence and upregulate gene expression
- Capability for single-patient programs targeting ultra-rare conditions where conventional clinical development is not feasible